

Appl. No. 09/932,538
Response to Office Action of February 21, 2006
Page 3 of 4

Remarks/Arguments:

Upon entry of the present amendment, claims 5 and 7 will be pending in this application. Claim 5 has been amended to include a size range of less than about 1000 nm, removing the argument that the particles are as large as the Nuwayser particles. This size range clearly distinguishes the claimed particles over those described by the Nuwayser reference and support for this amendment appears in the specification at least at page 12. The claims have also been amended to clarify the particular mucosal surfaces being treated. This also removes the argument that the suppository delivery of Nuwayser anticipates or renders obvious claimed delivery routes. Support for this amendment appears in the specification at least at pages 12 and 15.

Finally, as the Examiner has acknowledged, the Nuwayser reference is directed to drug delivery vehicles, not to particles for inducing immunity. Claim 5 has been amended to clarify that inducing immunity is the purpose of the claimed method, and to include that recitation in the body of the claim (and not only in the preamble).


Upon allowance of the pending claims, a terminal disclaimer will be filed to address the Examiner's double patenting concerns.

Appl. No. 09/932,538
Response to Office Action of February 21, 2006
Page 4 of 4

CONCLUSION

Applicants believe that the currently pending claims are in condition for allowance and respectfully request issuance of a patent containing these claims in due course. If there remain any additional issues to be addressed, the Examiner is urged to contact the undersigned attorney at 404.815.6147.

Respectfully submitted,



Kristin M. Crall
Reg. No. 46,895

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia, 30309-4530
404.815.6147